	US 11,674,157 B2
	Donor plasmid vectors
Xiao-Wen Cheng, Oxford, OH (US); Hui Shang, Oxford, OH (US); and Tyler Garretson, Oxford, OH (US)
Assigned to Miami University, Oxford, OH (US)
Filed by Miami University, Oxford, OH (US)
Filed on Jun. 19, 2018, as Appl. No. 16/12,686.
Claims priority of provisional application 62/521,787, filed on Jun. 19, 2017.
Prior Publication US 2019/0002918 A1, Jan. 3, 2019
Int. Cl. C12N 15/86 (2006.01); C12N 15/866 (2006.01)

CPC C12N 15/866 (2013.01) [C12N 15/86 (2013.01); C12N 2710/14121 (2013.01); C12N 2710/14143 (2013.01)]

4 Claims

1. A method of improving protein expression in a cell capable of being infected by AcMNPV comprising:

(i) providing a first AcMNPV sequence that has been modified to comprise a heterologous nucleic acid encoding a cis element having 95% to 100% identity to SEQ ID NO:1, a polh promoter, a polh ORF, and a polh pA signal sequence; wherein the cis element is located 147 bp upstream of the polh promoter to form a first modified AcMNPV bacmid, and

(ii) infecting the cell with the first modified AcMNPV bacmid, wherein the cell infected with the first modified AcMNPV bacmid expresses at least 3 times the level of polyhedrin protein as compared to a cell infected with a second AcMNPV bacmid comprising a SV40 pA signal sequence.